A detailed history of Front Row Advisors LLC transactions in Organon & Co. stock. As of the latest transaction made, Front Row Advisors LLC holds 3 shares of OGN stock, worth $44. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3
Previous 13 76.92%
Holding current value
$44
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$18.65 - $23.03 $186 - $230
-10 Reduced 76.92%
3 $0
Q1 2024

May 14, 2024

BUY
$13.78 - $18.8 $137 - $188
10 Added 333.33%
13 $0
Q4 2023

Feb 15, 2024

SELL
$10.95 - $17.32 $109 - $173
-10 Reduced 76.92%
3 $0
Q1 2023

May 22, 2023

BUY
$21.42 - $32.08 $278 - $417
13 New
13 $0
Q4 2022

Feb 15, 2023

BUY
$23.31 - $28.61 $233 - $286
10 New
10 $0
Q2 2022

Aug 15, 2022

SELL
$31.66 - $38.9 $918 - $1,128
-29 Closed
0 $0
Q4 2021

Mar 09, 2022

BUY
$28.67 - $37.13 $458 - $594
16 Added 123.08%
29 $1,000
Q2 2021

Aug 23, 2021

BUY
$28.45 - $38.0 $369 - $494
13 New
13 $0

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $3.75B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Front Row Advisors LLC Portfolio

Follow Front Row Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Front Row Advisors LLC with notifications on news.